Skip to main content
. 2020 Feb 4;9(1):119–135. doi: 10.1007/s40121-020-00281-x

Table 4.

Univariate analysis of variables associated with 14-day mortality

Variables Alive
(n = 93)
Dead
(n = 16)
p value*
Age (years), mean ± SD 66.3 ± 13.6 72.1 ± 15.3 0.13
Male, n (%) 62 (66.7) 11 (68.8) 1
Department, n (%)
 Surgical ward 34 (36.6) 2 (12.5) 0.08
 Medical ward 29 (31.2) 9 (56.3) 0.08
 ICU stay 21 (22.6) 2 (12.5) 0.51
 Oncology-hematology ward 9 (9.7) 3 (18.8) 0.37
Underlying disease, n (%)
 Solid tumor 52 (55.9) 8 (50.0) 0.78
 Gastrointestinal disease 38 (41.3) 6 (37.5) 1
 Diabetes mellitus 23 (24.7) 3 (18.8) 0.75
 Neurologic disease 23 (24.7) 3 (18.8) 0.75
 Cardiovascular disease 19 (20.4) 6 (37.5) 0.19
 Liver disease 13 (14.1) 2 (12.5) 1
 Hematologic malignancy 4 (4.3) 2 (12.5) 0.21
 Charlson comorbidity index 3.6 ± 2.6 3.4 ± 2.4 0.75
Risk factor, n (%)
 Central venous catheter 75 (80.6) 11 (68.8) 0.32
 Total parenteral nutrition 62 (66.7) 8 (50.0) 0.26
 Previous abdominal surgery 40 (43.0) 5 (31.3) 0.42
 Corticosteroids 28 (30.1) 6 (37.5) 0.56
 Previous antifungals 24 (25.8) 7 (43.8) 0.23
 Neutropenia 6 (6.5) 2 (12.5) 0.33
 Immunosuppressive therapy 7 (7.5) 1 (6.3) 1
 Pitt score, median (IQR) 0 (0–2) 0 (0–1) 0.46
Clinical manifestation, n (%)
 Sepsis 35 (37.6) 5 (31.3) 0.78
 Severe sepsis 28 (30.1) 3 (18.8) 0.54
 Septic shock 8 (8.6) 4 (25.0) 0.07
Candida species, n (%)
 C. albicans 47 (50.5) 9 (56.3) 0.78
 C. parapsilosis 24 (25.8) 3 (18.8) 0.75
 C. glabrata 13 (14.0) 2 (12.5) 1
 C. krusei 4 (4.3) 2 (12.5) 0.21
 C. tropicalis 4 (4.3) 0 1
 Other Candida species 3 (3.2) 0 1
Source, n (%)
 Central venous catheter 60 (64.5) 5 (31.3) 0.02
 Intra-abdominal 14 (15.1) 4 (25.0) 0.29
 Primary 8 (8.6) 5 (31.3) 0.02
 Urinary tract 6 (6.5) 1 (6.3) 1
 Other sourcesb 5 (5.4) 1 (6.3)
Initial antifungal therapy, n (%)
 Fluconazole 63 (67.7) 11 (68.8) 1
 Echinocandins 25 (26.8) 4 (25.0) 1
 Liposomal amphotericin B 5 (5.3) 1 (6.3) 1
 Early adequate antifungal therapy, n (%) 85 (91.4) 13 (81.3) 0.20
 Early adequate source control of infection, n (%) 73 (93.6) 5 (55.6) 0.006
 Persistent candidemia, n (%) 21 (23.1) 2 (20.0) 1
 Ocular candidiasis, n (%) 15 (16.9) 0 0.59
 Infective endocarditis, n (%) 2 (2.3) 0 1
 ICU admission due to candidemia, n (%) 6 (6.5) 4 (25.0) 0.04
 Intervention period, n (%) 50 (53.8) 3 (18.8) 0.01
 All bundle elements successfully completed, n (%) 65 (69.9) 5 (31.3) 0.004

ICU intensive care units

aOther Candida species include: 1 C. lusitaniae, 1 C. dublinensis and 1 C. incospicua

bOther sources include: 1 chorioamnionitis, 2 peripheral catather; 2 infective endocarditis, 1 infection from prosthesis

*P values < 0.05 are shown in bold